melanotan and melanotan 2 II Melanotan 2 (MT2) | Modern

Gdap1-null motor neurons display a fragile cell phenotype prone to early degeneration showing (1) altered mitochondrial morphology, with an increase in the fragmentation of these organelles, (2) activation of autophagy and mitophagy, (3) abnormal metabolism, characterized by a downregulation of Hexokinase 2 and ATP5b proteins, (4) increased reactive oxygen species and elevated mitochondrial membrane potential, and (5) increased innate immune response and p38 MAP kinase activation

The multiple-dose containers are packaged 24 per case (NDC 64980-503-12)

Current Drug Targets

Some medications may interact with the fluids and nutrients in the IV, so its important to discuss your medication history beforehand

Popov A, Brazhe A, Denisov P, Sutyagina O, Li L, Lazareva N, Verkhratsky A, Semyanov A (2021) Astrocyte dystrophy in ageing brain parallels impaired synaptic plasticity